07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

DS Biopharma deal

DS Biopharma spun out Afimmune, which will focus on fibrotic and pulmonary diseases. The newco will develop DS Biopharma’s DS102 and other undisclosed preclinical compounds. DS102, a bioactive lipid produced by the non-enzymatic oxidation of...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Clinical News

15-HEPE: Phase I data

A double-blind, placebo-controlled Phase I trial in 56 healthy volunteers showed that single and multiple doses of oral DS102 for 28 days were well tolerated with no serious adverse events or discontinuations due to adverse...